ABSTRACT -Purpose. MPTP-induced dopaminergic degeneration is an experimental model commonly used to explore Parkinson's disease. Cerebral drug transport by ABC transporters in MPTP models has never been reported. We have investigated the role of ABCB1 and ABCG2 on the bromocriptine transport through the blood-brain barrier (BBB) in a murine MPTP model. Methods. The bromocriptine transport was investigated by measuring brain and plasma concentrations of bromocriptine after ip administration in MPTP mice. The BBB integrity was controlled by measuring the brain vascular volume of two vascular space markers, [ 
INTRODUCTION
Parkinson's disease (PD) is primarily a neurodegenerative disorder characterized by a large loss of nigral dopaminergic neurons with dopamine depletion and formation of Lewy bodies. PD treatment consists in the administration of dopamine receptor agonists and levodopa, as dopamine does not cross the bloodbrain barrier (BBB). It has been postulated that exogenous toxicants, including pesticides, might be involved in the etiology of PD (1). Several in vivo models of dopaminergic degeneration, using neurotoxins such as rotenone, 6-hydroxydopamine (6-OHDA) or MPTP, have been developed to study PD (2) (3) (4) . MPTP, and its metabolite MPP + , are potent and specific nigral toxins able to inhibit the complex I of the mitochondrial electron transport chain (5) . The model of MPTP intoxication is an interesting model for the earliest phase of PD where clinical symptoms appear and neuroprotective therapy should be introduced.
Drugs used for PD treatment need to cross the brain capillary wall to be active. Only small molecules with high lipid solubility and low molecular mass (<400 Da) cross the BBB by passive process in pharmacologically significant amounts. Many other drugs are transported across the BBB by an active transport. Conversely, cerebral efflux pumps are expressed on the luminal side of BBB endothelial cells and are responsible for the extrusion of their substrates from endothelial cells back to the blood circulation. Among the efflux transporters, ABCB1 (Pglycoprotein, P-gp) and ABCG2 (Breast Cancer Resistance Protein, BCRP) are two pumps of the family of ATP-binding Cassette transporters (ABC transporters). ABCB1 was first described by Juliano et al as a chemotherapic exporter in multidrug resistant tumors (6) . Several antiparkinsonian drugs have been tested for interactions with efflux or influx transporters. Among them, levodopa and bromocriptine. Levodopa is a major treatment in PD whereas dopamine agonists are used in mild forms of disease. Bromocriptine, a dopamine agonist is still used, despite of its adverse effects, alone or combinated with levodopa.
ABBREVIATIONS
Levodopa crosses BBB through LAT1 (Large neutral Amino-acid Transporter) and is converted in dopamine within the brain by aromatic amino acid decarboxylase (AAAD). While Soares-da-Silva et al. have shown that levodopa is excluded from brain capillary endothelial cells by ABCB1 (7, 8) , other authors showed that levodopa does not interfere with ritonavir uptake by ABCB1 expressing cells (9) . Bromocriptine, an antiparkinsonian drug which is also a substrate of ABCB1, is weakly transported in cerebral tissues and low concentrations are detected in mice brain (10 (13) . ABCG2 also plays a role in drug efflux of many drugs but interactions between ABCG2 and bromocriptine have not been described.
Multidrug resistance occurs in several diseases such as inflammation, cancer or epilepsy (14) (15) (16) . Pharmacoresistance is often related to ABCB1 overexpression and has been widely described in these diseases (17, 18) . However, few data are available on the expression and function of ABCB1 in PD. Alterations of BBB associated with a compensatory increase of ABCB1 expression were observed in mice exposed to the neurotoxin 6-hydroxydopamine, suggesting that brain distribution of drugs would be modified (19) . Hence, the aim of this study was to investigate the transport of bromocriptine through the BBB and understand the influence of dopaminergic degeneration on its efflux by ABCB1 and ABCG2 functionality, in a model of MPTP-induced Parkinsonism syndrome. MPTP can impair BBB integrity. As large amounts of this neurotoxin are required to achieve neurodegeneration, we also had to explore BBB integrity. 
METHODS

Reagents
Animals
Male C57BL/6N mice (Janvier, Le Genest-SaintIsle, France), 7-8 weeks-old (25g) were used in these studies. Animal housing, handling and experimentations were performed in accordance with the European Communities Council directive of 11/24/1986 (86/609/EEC).
Acute MPTP intoxication protocol
The MPTP-treated groups received intraperitoneal (ip) injections of MPTP every 2 hours (4 x 15 mg.kg -1
) and control-groups received saline solution every 2 hours (4 times, ip) with equivalent volumes at day 0. All injections were given in a volume of 250 µL/25g of body weight. This experimental model was previously validated by Rousselet et al. (20) who showed that MPTP injections led to a loss of nigral dopaminergic neurons, a reduction in striatal dopamine content and a behavioural disturbance. As reported by the authors, in this murine model, all animals exhibit an homogeneous and severe loss (90%) of dopamine content (20) . All experiences were conducted on day 7, since MPTP and metabolites were completely excreted and neurotoxicity by close contact was void (21) . Blood was collected by intracardiac puncture after anesthesia with isoflurane. The brain was collected after euthanasia. Plasma and brain samples were stored frozen at -80°C until analysis.
Transport study of bromocriptine through the BBB
BCT was administered to MPTP-treated mice and saline-treated mice, at the dose of 20 mg.kg In each group (n=9), BCT was administered by ip route 30 min after PSC833 injection, corresponding with its plasmatic T max . The same schedule was followed for the control group.
Brain and plasma were collected 1 hour after BCT injection. BCT concentration was determined in brain and plasma by HPLC using an analytical method validated in our laboratory and previously reported (10) . Briefly, the analytical separation was achieved using a Lichrospher ® 100 RP18 column (150 x 4.6 mm, 5 µm) with a fluorimetric detection ( ex : 330 nm;  em : 405 nm) and a mobile phase composed of water with 0.2% diethylamine (pH adjusted to pH3.0) and acetonitrile (70:30, v/v) running at a flow rate of 1 mL.min -1
. BCT was extracted from brain and plasma using MCX ® OASIS cartridges (60 mg, 3 mL) (Waters, Millipore, Saint Quentin, France) with 1 mL of methanol/ammonia (97.5:2.5; v/v).
Brain tissue total BCT was corrected for vascular contamination using the following formula:
where Q total brain is the total BCT amount in brain, including cerebral capillaries and cerebral tissue, Q cap is the BCT amount in cerebral capillaries and Q tissue is the BCT amount in brain tissue. Q cap was calculated as: ). The thorax of the mouse was opened and the heart was cut. Perfusion was immediately started (flow rate: 2.5 mL.min −1 ) with the syringe containing the perfusion fluid placed in an infusion pump (Harvard pump PHD 2000, Harvard Apparatus, Holliston, MA, USA) and connected to the catheter. The perfusion fluid consisted of bicarbonate-buffered physiological saline (mM): 128 NaCl, 24 NaHCO 3 , 4.2 KCl, 2.4 NaH 2 PO 4 , 1.5 CaCl 2 , 0.9 MgCl 2 and 9 D-glucose. The solution was gassed with 95% O2 and 5% CO2 for pH control (7.4) and warmed to 37°C in a water bath. Appropriate concentrations of compounds were added to the perfusate. Each mouse was perfused with [ ). Perfusion was terminated by decapitation at 60 s. The brain was removed from the skull and dissected out on ice. Each right cerebral hemisphere was placed in a tared vial and weighed. Aliquots of the perfusion fluid were also collected and weighed to determine tracer concentrations in the perfusate. Samples were digested in 1 mL of Soluène ® at 50°C and mixed with 10 ml of Ultima gold ® counting fluid (Perkin-Elmer Life and Analytical Sciences, Boston, USA). Radioactivity was determined by liquid scintillation counting on a Beckman LS 6000 TA counter (Beckman, Galway, Ireland).
Calculation of brain vascular volume (Vvasc)
The calculation of the brain vascular volume has previously been described (23, 24) . The brain vascular volume (Vvasc, µl.g 
Investigation of ABCB1 and ABCG2 functionality
A well known and validated ABCB1 substrate, [ 3 H]-digoxin, was administered to MPTP-treated mice and saline-treated mice, at 0.5 mg/kg (1µCi/mice) to investigate ABCB1 activity. Plasma and brains were collected 6 hours after administration of [ 3 H]-digoxin. Dose and timing of sampling were extrapolated from previous published data : 6 hours were chosen as the equilibrium time of brain/plasma concentration ratio (22, 25, 26 
Investigation of ABCB1 and ABCG2 expression
Isolation of brain capillaries
Brain microvessels were isolated from mice brains by using the capillary depletion method of Triguero et al. (27) with slight modifications. After euthanasia, brains were removed from mice skulls and promptly immerged in ice-cold phosphate-buffered saline (PBS; Invitrogen Corporation, Cergy-Pontoise, France). They were then cleared of cerebellum, hind-and midbrain, superficial blood vessels, and meninx. Afterwards, half of the remaining cortex was gently homogenized in ice-cold Dulbecco's modified Eagles medium/fetal calf serum (DMEM/FCS; 90:10; v:v) (Invitrogen Corporation) by using a Teflon potter. The homogenates were next centrifuged at 1,000 g for 10 min. After elimination of the supernatant, pellets were homogenized in 5 mL of a 25% BSA solution and centrifuged again at 1,500 g for 20 min. Supernatants were thereafter removed and pellets were suspended in 1 mL of the same icecold mixture of DMEM/FCS and filtrated at 60 μm. Filtrates containing brain capillaries were centrifuged at 12,000 g for 45 min. Pellets of capillaries were washed and resuspended in icecold PBS. Microvessels suspensions were finally centrifuged at 12,000 g for 20 min. Pellets were immediately prepared for protein extraction and semi-quantification.
Semi-quantification of ABCB1 and ABCG2 expression by Western Blot
Proteins were extracted from the crude membranes with a TENTS solution (1M Tris, 0.5M EDTA, 3M NaCl, 10% Triton, 20% SDS) with a protease inhibitor cocktail (1 mM PMSF, 2 mM Benzamidine, 7.3 µM pepstatine, 5 µg/mL aprotinin and 20 µg/mL leupeptin) for 60 min under gentle shaking. Once centrifuged (12000 rcf; 20 min), the supernatants were stored at -20°C before quantification of total proteins using bicinchoninic acid protein assay kit (SigmaAldrich). Ten µg of proteins were dissolved in electrophoresis sample buffer containing β-mercapto-ethanol and separated on a 8% SDSPolyacrylamide gel. Resolved proteins were transferred to nitrocellulose membranes and subjected to immunoblot analysis. The blots were blocked 1 hour in TBS buffer containing 0.05% Tween 20 (TTBS) and 10% non-fat dry milk. After washing with TTBS, the blots were incubated 2 hours at room temperature with 1:200 dilution of monoclonal anti-ABCB1 antibody C219 (Dako, Glostrup, Denmark) or with a 1:40 dilution of monoclonal anti-ABCG2 antibody BXP-53 (Alexis, Paris, France), with a 1:5000 dilution of anti-β-actin antibody clone AC74 (Sigma-Aldrich).
After 5 times of 10 min washes in TTBS, they were further incubated 1 hour at room temperature with anti-mouse horseradish peroxidase-conjugated antibody diluted to 1:10000 (Dako, Glostrup, Denmark). The membranes were washed 5 times for 10 min in TTBS and then probed using the Western Lightning chemiluminescence reagent (Perkin Elmer; Courtaboeuf, France). The intensity of bands was quantified using Scion Image (NIH, Scion Corporation, Bethesda, USA) and protein expression was normalized with β-actin.
Statistical analysis
All data are expressed as mean ± SEM. A non parametric Mann-Whitney test was used for statistical analysis. P<0.05 was considered statistically significant.
RESULTS
Bromocriptine transport by ABCB1 through the BBB
In group 1 (control mice treated with placebo), cerebral uptake of BCT was poor with a mean brain/plasma concentration ratio of 0.075 ± 0.016 (n=9) (Figure 1 ). In group 2, (control mice treated with PSC833), the inhibitor increased BCT uptake by 2.2-fold in control mice (0.155 ± 0.031, n=9, p<0.02). In group 3 (MPTP mice treated with placebo) the cerebral uptake of BCT was increased by 2.3-fold compared with group 1 (0.175 ± 0.020, n=9, p<0.001). Conversely, no difference was observed between groups 3 and 4 (MPTP mice treated without or with PSC833). (24) . This discrepancy should be attributed to the lower molecular weight and higher permeability of sucrose relative to inulin (28) .
Determination of the BBB integrity by in situ
ABCB1 and ABCG2 functionality
Digoxin was chosen as a substrate of ABCB1 in order to investigate the functionality of this efflux pump. We did not observe any significant difference in brain/plasma ratios between MPTPtreated mice and control mice ( Table 2) .
Prazosin was chosen as ABCG2 substrate to investigate its functionality. We did not observe any difference in brain/plasma ratios between MPTP-treated mice and control mice ( Table 2) . Inhibition of ABCB1 and ABCG2 activity was validated with PSC833 and GF120918, a specific inhibitor of ABCB1 and an inhibitor of ABCG2. We have shown that digoxin and prazosin brain transport were increased in PSC833 and in GF120918-treated animals (data not shown).
Hence, intoxication with MPTP did influence neither ABCB1 nor ABCG2 functionality.
ABCB1 and ABCG2 expression at the BBB
There was a difference in the expression of efflux transporters in cerebral capillaries of MPTPtreated mice compared to that of saline-treated mice: in brain capillaries from MPTP mice, ABCB1 expression was increased by 1.43-fold (p<0.05) when compared to that of control mice (Figure 2 ). On the other hand, ABCG2 expression was decreased by 1.3-fold when compared to that of control mice ( Figure 3 ) Table 2 . Brain/plasma ratios of probe substrates (mean ± SEM) in ABCB1 and ABCG2 functionality study, after single ip injection of substrates in control mice and MPTP-treated mice. 
DISCUSSION
Our study shows that intoxication of mice with MPTP enhances brain distribution of BCT. In order to explain this phenomenon, we have hypothesized that (i) BBB permeability is increased by MPTP and/or (ii) that MPTP is responsible for an alteration of BCT efflux by transporters from the brain, resulting in its accumulation. MPTP was used as a validated model of PD. Rousselet et al. have previously shown that MPTP-treated mice exhibit loss of dopaminergic neurons and dopamine content (20) . In their study, they did not evidence any failure in intoxication. As we needed the whole brain to perfom drug (bromocriptine, prazosin and digoxine) or protein quantification, we could not check by immunohistochemistry to what extent were affected dopamine neurons.
As BBB permeability can influence brain diffusion of xenobiotics and may be disrupted by some toxics, we have investigated BBB integrity. BBB is characterized by tight junctions and adhesin molecules, between brain microvessel endothelial cells, that prohibit the crossing of xenobiotics (29) . Brain vascular permeability is increased by cerebral ischemia, infections or inflammatory diseases like cerebral malaria (30) . Experimental models of cerebral malaria after infection of C57BL/6N mice with Plasmodium berghei K173 have evidenced an increase of vascular permeability and cerebral oedema, permitting to epileptogene factors, to cross the BBB (30) (31) (32) . MPTP was also responsible for brain inflammation that led to a second-time microglial activation which generated neuronal destruction (33) . Studies using deficient mice in COX-2 gene, inductible NO synthase gene or TNF receptors, all of them playing a role in inflammatory process, showed that blockade of microglial activation has a neuroprotective effect against MPTP toxicity (34) (35) (36) (37) . They have shown that the neuronal NO synthetase was markedly decreased in the substantia nigra 3 and 7 days after MPTP treatment. In another rat model of glial cell degeneration, Guerin et al. have demonstrated that BBB integrity was largely re-established within 6 days after intoxication by dinitrobenzene (38) . In conclusion, the increase of BCT cerebral uptake observed in our experiments could not be the outcome of an alteration of BBB integrity. The second hypothesis to explain the increase in BCT cerebral diffusion in MPTP mice is an alteration of functionality and/or expression of efflux transporters involved in BCT cerebral transport. We have already reported elsewhere that BCT is transported by ABCB1 (10) . The accumulation of BCT in brain of PSC833 pretreated mice confirmed this result. However, ABCB1 inhibition by PSC833 does not modify brain distribution of BCT in MPTP-treated mice, suggesting that in these animals ABCB1 is not involved in BCT transport. Furthermore, digoxin transport is not modified by MPTP intoxication, showing that in MPTP treated animals, ABCB1 function is not altered.
In our experiments, ABCB1 expression was increased in MPTP animals. This increase could be explained by the inflammatory process (39) . Previous works reported that MDR1 transcription could be activated by a transcriptional regulator nuclear factor for Interleukin-6 (NF-IL6), a member of the C/EBPβ family of transcription factors. NF-IL6 is inductible by stress or inflammation and would be able to induce MDR1 expression (40) . ABCB1 expression is also up-regulated by the steroid xenobiotic receptor SXR (pregnant X receptor, PXR in rodents) which is a member of a family of ligand-activated nuclear receptor that regulate expression of drug metabolizing enzymes and transporters. This activation was demonstrated in rat brain capillaries where PXR ligands enhanced ABCB1 expression (41) . Relations between MPTP or MPP + and SXR/PXR have not been described in literature. However, MPTP or MPP + could be a PXR-ligand or another nuclear receptor ligand which up-regulates ABCB1 expression in brain capillaries.
The increase of ABCB1 expression is not followed by an increase of ABCB1 functionality as digoxin transport is not altered by MPTP intoxication. Examples of lack of correlation between ABCB1 expression and ABCB1 activity have already been reported in many assays. Hence, the increase of cerebral uptake of BCT does not result from an alteration of transport via ABCB1. Recent studies have demonstrated that ABCG2 exerts an impact on drug absorption and disposition (46) . We have demonstrated that ABCG2 function is not altered by the dopaminergic neurodegeneretion but its cerebral expression decreases following MPTPinduced intoxication. Literature doesn't report any case of discrepancy between ABCG2 expression and functionality.
Our studies showed that ABCB1 expression was increased whereas ABCG2 expression was decreased. Compensation between efflux transporters expression has already been described in vivo, in deficient mouse models : in mutant CF-1 mdr1a(-/-) mice, the lack of in cerebral ABCB1 is associated with an increase of ABCG2 mRNA at the BBB compared to wildtype mice.
However, many other proteins belonging to the ABC transporters family are present at the BBB such as MRPs (47) or uptake transporters (organic anion transporter polypeptid Oatp2, Oatp14, LAT1) (48) . We suppose that high levels of the neurotoxin MPTP, necessary to achieve the neurodegenerative model, could also alter other transporters implicated in cerebral uptake or efflux.
In conclusion, our assays show that, in a model of dopaminergic neurodegeneration, BCT brain diffusion is increased. This phenomenon which could lead to central toxicity of BCT and increase of adverse events in patients is not related to ABCB1 or ABCG2 dysfunction. Furthermore, our work gives one more example of discrepancy between ABCB1 expression and functionality.
